The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.
Rathin C. Das, PhD
Advertisement
Rathin Das, PhD, MBA, is chief executive officer of Synergys Biotherapeutics, 1945 Arbol Grande, Walnut Creek, CA 94595, [email protected]
Articles by Rathin C. Das, PhD
Innovative products and a range of indications drive the therapeutic antibody market.
Advertisement
Latest Updated Articles
Angiopoietins: Novel Targets for Anti-angiogenesis TherapyOctober 1st 2013
Therapeutic Antibodies in ReviewFebruary 1st 2013
Advertisement
Advertisement